Viral Hepatitis

You have full text access to this OnlineOpen article

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus†

  1. Juan Berenguer1,‡,§,*,
  2. Julio Álvarez-Pellicer2,
  3. Pilar Miralles Martín1,
  4. José López-Aldeguer3,
  5. Miguel Angel Von-Wichmann4,
  6. Carmen Quereda5,
  7. Josep Mallolas6,
  8. José Sanz7,
  9. Cristina Tural8,
  10. José María Bellón1,
  11. Juan González-García2,‡,
  12. The GESIDA3603/5607 Study Group

Article first published online: 2 JUL 2009

DOI: 10.1002/hep.23020

Issue

Hepatology

Hepatology

Volume 50, Issue 2, pages 407–413, August 2009

Additional Information

How to Cite

Berenguer, J., Álvarez-Pellicer, J., Martín, P. M., López-Aldeguer, J., Von-Wichmann, M. A., Quereda, C., Mallolas, J., Sanz, J., Tural, C., Bellón, J. M., González-García, J. and The GESIDA3603/5607 Study Group (2009), Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology, 50: 407–413. doi: 10.1002/hep.23020

Author Information

  1. 1

    Hospital Gregorio Marañón, Madrid, Spain

  2. 2

    Hospital La Paz, Madrid, Spain

  3. 3

    Hospital La Fe, Valencia, Spain

  4. 4

    Hospital Donostia, San Sebastián, Spain

  5. 5

    Hospital Ramón y Cajal, Madrid, Spain

  6. 6

    Hospital Clinic, Barcelona, Spain

  7. 7

    Hospital Príncipe de Asturias, Alcalá de Henares, Spain

  8. 8

    Hospital Germans Trias i Pujol, Badalona, Spain

  1. ‡

    These authors contributed equally to this study.

  2. §

    fax: +34 91 426 5177.

*Unidad de Enfermedades Infecciosas/VIH (4100), Hospital Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain

  1. †

    Potential conflict of interest: Dr. Tural advises Abbott and GlaxoSmithKline. She is on the speakers' bureau of Gilead.

Publication History

  1. Issue published online: 29 JUL 2009
  2. Article first published online: 2 JUL 2009
  3. Manuscript Accepted: 6 APR 2009
  4. Manuscript Received: 9 NOV 2008

Funded by

  • Fundación para la Investigación y la Prevención del SIDA en España (FIPSE). Grant Number: Ref. 36443/03 and 36702/07
  • Fondo de Investigación de la Seguridad Social en España (FIS) [Spanish Social Security Foundation for Research]. Grant Numbers: Ref. EC07/90734, Ref RD07/0006/2007
  • Red de Investigación en SIDA [AIDS Research Network] (RIS)
  • FIS. Grant Number: Ref. PI080928

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (208K)

References

  • 1
    Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602–610.
  • 2
    Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562–569.
  • 3
    Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1–5.
  • 4
    Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87: 555–561.
    Direct Link:
  • 5
    Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492–497.
  • 6
    Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207–1214.
  • 7
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438–450.
  • 8
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451–459.
  • 9
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839–2848.
  • 10
    Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27–F36.
  • 11
    Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004; 99: 636–644.
    Direct Link:
  • 12
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677–684.
  • 13
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. HEPATOLOGY 1994; 20: 15–20.
    Direct Link:
  • 14
    Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593–602.
  • 15
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–1313.
  • 16
    Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. HEPATOLOGY 2004; 39: 333–342.
    Direct Link:
  • 17
    Lawson A, Hagan S, Rye K, Taguri N, Ratib S, Zaitoun AM, et al. The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol 2007; 47: 37–45.
  • 18
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007; 45: 579–587.
    Direct Link:
  • 19
    Lissen E, Clumeck N, Sola R, Mendes-Correa M, Montaner J, Nelson M, et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20: 2175–2181.
  • 20
    Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008; 46: 768–774.
  • 21
    Barreiro P, Labarga P, Martin-Carbonero L, Amor A, Ruiz-Sancho A, Castellares C, et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther 2006; 11: 869–877.
View Full Article (HTML) Get PDF (208K)